Pub. Date : 2015 Aug
PMID : 26323924
6 Functional Relationships(s)Download |
Sentence | Compound Name | Protein Name | Organism |
| 1 | The genotype of ribonucleotidereductase M1 -269C > A is associated with the response to platinum-based chemotherapy and as a prognostic biomarker in advanced nonsmall cell lung cancer. | Platinum | ribonucleotide reductase catalytic subunit M1 | Homo sapiens |
| 2 | PURPOSE: Genetic polymorphisms of ribonucleotidereductase M1 (RRM1) was a DNA repair gene, which may affect patients" response to platinum-based chemotherapy or gemcitabine-based chemotherapy. | Platinum | ribonucleotide reductase catalytic subunit M1 | Homo sapiens |
| 3 | PURPOSE: Genetic polymorphisms of ribonucleotidereductase M1 (RRM1) was a DNA repair gene, which may affect patients" response to platinum-based chemotherapy or gemcitabine-based chemotherapy. | Platinum | ribonucleotide reductase catalytic subunit M1 | Homo sapiens |
| 4 | We retrospectively assessed whether single nucleotide polymorphisms (SNPs) of RRM1 can be used to predict overall survival (OS), progression free survival and response in nonsmall cell lung cancer (NSCLC) patients treated with platinum-based regimens as first-line chemotherapy. | Platinum | ribonucleotide reductase catalytic subunit M1 | Homo sapiens |
| 5 | CONCLUSION: The genotype of RRM1 -269C > A was significantly associated with platinum-based chemotherapy sensitivity in smoking patients and can be used to predict OS in advanced NSCLC patients who received platinum-based chemotherapy or gemcitabine-based chemotherapy. | Platinum | ribonucleotide reductase catalytic subunit M1 | Homo sapiens |
| 6 | CONCLUSION: The genotype of RRM1 -269C > A was significantly associated with platinum-based chemotherapy sensitivity in smoking patients and can be used to predict OS in advanced NSCLC patients who received platinum-based chemotherapy or gemcitabine-based chemotherapy. | Platinum | ribonucleotide reductase catalytic subunit M1 | Homo sapiens |